Home > Magazine > Society

2011 Annual Meeting Abstracts Garner Major Media Coverage

Jun 23, 2011

Research from the 2011 ASCO Annual Meeting received a significant amount of media attention. In particular, studies demonstrating advances in the treatment of melanoma, ovarian, and lung cancers received the most attention, garnering coverage in top national consumer and trade media outlets. The results from a large trial on reducing the risk of breast cancer also received a considerable amount of coverage.

The melanoma-related studies referenced above include a phase III trial that showed vemurafenib was the first drug to improve overall survival when compared to chemotherapy in patients with advanced melanoma (Abstract LBA4), as well as a phase III study that found that first-line treatment with a combination of ipilimumab and dacarbazine improved overall survival in patients with previously untreated metastatic melanoma (Abstract LBA5). Both studies earned coverage by the Associated Press, Reuters, HealthDay, NBC Nightly News, ABC World News Tonight, CNN, Bloomberg Television, USA Today, New York Times, Wall Street Journal, Los Angeles Times, Washington Post, and WebMD, to name a few.

Studies showing that bevacizumab extends progression-free survival in recurrent ovarian, peritoneal, and fallopian tube cancers (Abstract LBA5007), as well as a study showing that pemetrexed maintenance therapy improves progression-free survival in patients with advanced lung cancer (Abstract CRA7510), received coverage in outlets such as Reuters, Bloomberg, LosAngeles Times, and Medscape.

The study finding that exemestane reduced the risk of breast cancer in women at increased risk of the disease (Abstract LBA504) gained coveragein the Associated Press, Reuters,USA Today, Boston Globe, and MedPage Today.

Back to Top